We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+8.67%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.15B
AUM Growth
-$198M
Cap. Flow
-$329M
Cap. Flow %
-10.43%
Top 10 Hldgs %
41.12%
Holding
79
New
11
Increased
20
Reduced
24
Closed
8

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$70.4M
2
MBX
MBX Biosciences
MBX
+$69M
3
IMVT icon
Immunovant
IMVT
+$43.2M
4
ORKA
Oruka Therapeutics
ORKA
+$43M
5
GH icon
Guardant Health
GH
+$42.5M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$180M
2
INSM icon
Insmed
INSM
+$134M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$122M
4
AXSM icon
Axsome Therapeutics
AXSM
+$86.9M
5
TVTX icon
Travere Therapeutics
TVTX
+$71.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$54.9B
$198M 6.28%
365,000
-35,000
-9% -$17.7M
DVAX
2
DELISTED
Dynavax Technologies
DVAX
$140M 4.43%
12,526,486
+1,626,486
+15% +$17.9M
GH icon
3
Guardant Health
GH
$18.9B
$138M 4.37%
6,000,560
+1,500,560
+33% +$42.5M
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$127M 4.03%
4,400,654
+1,900,654
+76% +$70.4M
IMVT icon
5
Immunovant
IMVT
$7.8B
$124M 3.93%
4,347,464
+1,463,728
+51% +$43.2M
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$123M 3.91%
3,843,900
+143,900
+4% +$5.38M
DYN icon
7
Dyne Therapeutics
DYN
$4.09B
$118M 3.74%
3,282,000
-718,000
-18% -$28.6M
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$117M 3.72%
1,600,693
+62,771
+4% +$4.72M
OCUL icon
9
Ocular Therapeutix
OCUL
$1.83B
$111M 3.51%
12,721,460
– –
NTLA icon
10
Intellia Therapeutics
NTLA
$1.5B
$102M 3.23%
4,950,000
+150,000
+3% +$3.46M
ALKS icon
11
Alkermes
ALKS
$8.08B
$98M 3.11%
3,500,000
– –
VRNA
12
DELISTED
Verona Pharma
VRNA
$91.5M 2.9%
3,180,025
-819,975
-20% -$20.2M
IONS icon
13
Ionis Pharmaceuticals
IONS
$9.03B
$88.1M 2.8%
2,200,000
+200,000
+10% +$9.31M
NRIX icon
14
Nurix Therapeutics
NRIX
$2.43B
$86.9M 2.76%
3,868,104
-123,396
-3% -$2.8M
VRDN icon
15
Viridian Therapeutics
VRDN
$2.14B
$85.3M 2.71%
3,750,945
-172,904
-4% -$2.83M
BCYC
16
Bicycle Therapeutics
BCYC
$269M
$80.3M 2.55%
3,548,001
+57,495
+2% +$1.33M
MBX
17
MBX Biosciences
MBX
$2.99B
$78.4M 2.49%
+3,018,935
New +$69M
AXSM icon
18
Axsome Therapeutics
AXSM
$11.8B
$77M 2.44%
857,219
-995,565
-54% -$86.9M
PLRX icon
19
Pliant Therapeutics
PLRX
$65.6M
$66.9M 2.12%
5,972,257
– –
APGE icon
20
Apogee Therapeutics
APGE
$10.1B
$58.7M 1.86%
1,000,000
– –
AUTL
21
Autolus Therapeutics
AUTL
$378M
$55.4M 1.76%
15,272,172
– –
GPCR icon
22
Structure Therapeutics
GPCR
$3.38B
$53.6M 1.7%
1,220,508
+270,508
+28% +$10.5M
OLMA icon
23
Olema Pharmaceuticals
OLMA
$983M
$47.8M 1.51%
4,000,000
– –
TERN
24
DELISTED
Terns Pharmaceuticals
TERN
$46.5M 1.48%
5,576,558
-523,442
-9% -$4.31M
FDMT icon
25
4D Molecular Therapeutics
FDMT
$495M
$44.3M 1.4%
4,096,452
+35,051
+0.9% +$582K
1
2 3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Deep Track Capital held 79 positions worth $3.15B, down 5.9% from $3.35B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deep Track Capital withdrew a net $329M in Q3 2024, closing 8 positions and reducing 24 holdings. Its most notable exit was Amgen, an estimated $180M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in MBX Biosciences worth $78.4M.

  • Deep Track Capital's largest Q3 2024 buy was MBX Biosciences: 3,018,935 shares worth $78.4M.
  • Deep Track Capital added most to Apellis Pharmaceuticals in Q3 2024, an estimated $70.4M increase.
  • Deep Track Capital's biggest Q3 2024 reduction was Axsome Therapeutics, cutting an estimated $86.9M.
  • Deep Track Capital fully exited Amgen in Q3 2024, selling an estimated $180M.
  • Deep Track Capital's ten largest holdings make up 41% of its $3.15B portfolio in Q3 2024.
  • Deep Track Capital opened 11 new positions and closed 8 in Q3 2024.
  • Deep Track Capital's portfolio value fell 5.9% quarter-over-quarter to $3.15B.

Based on Deep Track Capital's 13F filing for Q3 2024, filed 14 Nov 2024.